At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
LY2835219drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of LY2835219 in Japanese Patients With Advanced Cancer
In Brief
A Phase 1 clinical trial evaluating LY2835219 for Neoplasm Metastasis and Lymphoma. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm Metastasis, Lymphoma
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartDec 2013
Primary CompletionApr 2015
Study CompletionAug 2019
TodayJul 2026
First PostedDec 18, 2013
Enrollment StartDec 18, 2013
Primary CompletionApr 1, 2015
Study CompletionAug 21, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.5 years ago
Interventions
LY2835219drug
Administered orally